Development and evaluation of alternative material of sulpiride colloid for schizophrenia treatment
DOI:
https://doi.org/10.25118/2763-9037.2024.v14.1351Keywords:
Schizophrenia, Sulpiride, Cutaneous administrationAbstract
Introduction: sulpiride is a first-generation antipsychotic agent used for schizophrenia treatment. Its administration is oral, but is related to many side effects. Some of them are constipation, sedation, insomnia, weight gain, akathisia and parkinsonism. Because of those side effects, sulpiride's treatment adhesion becomes a great challenge. An alternative method for sulpiride's administration would be its application through the patient's skin. Such gel could offer many advantages over the traditional forms of drug administration, such as reduction in side effects, resulting in a greater treatment adhesion and consequently improvement on both positive and negative symptoms of schizophrenia. Objective: The purpose of this study is to develop an alternative administration system for sulpiride and evaluate its release in order that it can be incorporated to clinical practice in schizophrenic patients. Methods: We formulated a polivinilic alcohol and sulpiride solution, with the drug's concentrations at 50 mg and 100 mg. After the making of the solutions, we separated aliquots which were analyzed by a spectrophotometer that recorded the sulpiride's release. Results: The sulpiride solution of 50 mg got a release of, approximately, 50%, while the 100 mg solution got over 80% of release, both hitting a plateau after the study's first hour. Conclusion: sulpiride shows itself as a drug that can be used in a transdermal formulation. However, more studies are needed so it can be released extendedly.
Downloads
Metrics
References
Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014;39(9):638-45. PMID:25210417 - PMCID:PMC4159061
Picchioni MM, Murray RM. Schizophrenia. BMJ. 2007;335:91. https://doi.org/10.1136/bmj.39227.616447.BE DOI: https://doi.org/10.1136/bmj.39227.616447.BE
Silva RCB. Esquizofrenia: uma revisão. Psicol USP. 2006;17(4):263-85. https://doi.org/10.1590/S0103-65642006000400014 DOI: https://doi.org/10.1590/S0103-65642006000400014
Caley CF, Weber SS. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother. 1995;29(2):152-60. https://doi.org/10.1177/106002809502900210 PMID:7756714 DOI: https://doi.org/10.1177/106002809502900210
Lai EC, Chang CH, Kao Yang YH, Lin SJ, Lin CY. Effectiveness of sulpiride in adult patients with schizophrenia. Schizophr Bull. 2013;39(3):673-83. https://doi.org/10.1093/schbul/sbs002 PMID:22315480 - PMCID:PMC3627763 DOI: https://doi.org/10.1093/schbul/sbs002
Stahl SM. Fundamentos de psicofarmacologia de Stahl: guia de prescrição. Porto Alegre: Artmed; 2021.
Ritter JM, Flower R, Henderson G, Loke YK, MacEvan D, Rang HP. Rang & Dale: farmacologia. 9. ed. Barueri: GEN Guanabara Koogan; 2020.
Wiesel FA, Alfredsson G, Ehrnebo M, Sedvall G. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol. 1980;17(5):385-91. https://doi.org/10.1007/bf00558453 PMID:7418717 DOI: https://doi.org/10.1007/BF00558453
Ayoub AM, Ibrahim MM, Abdallah MH, Mahdy MA. Intranasal microemulgel as surrogate carrier to enhance low oral bioavailability of sulpiride. Int J Pharm Pharm Sci. 2016;8(10):188-97. https://doi.org/10.22159/ijpps.2016v8i10.13776 DOI: https://doi.org/10.22159/ijpps.2016v8i10.13776
Downloads
Published
How to Cite
Conference Proceedings Volume
Section
License
Copyright (c) 2024 Lucas Campos, Isabele Cyrillo, Jorge Henna Neto
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
